Skip to end of metadata
Go to start of metadata
You are viewing an old version of this page. View the current version.
Compare with Current
View Page History
« Previous
Version 16
Next »
| https://www.mdpi.com/2076-3425/14/3/246 |
| https://journals.sagepub.com/doi/abs/10.1177/07067437231210796 |
 Created by Anees Bahji, Gabriel Bastien, Paxton Bach, JinCheol Choi, Bernard Le Foll, Ron Lim, Didier Jutras-Aswad & M. Eugenia Socias.Prescription-type opioid use disorder (POUD) is often accompanied by comorbid anxiety, yet the impact of anxiety on retention in opioid agonist therapy (OAT) is unclear. Therefore, this study investigated… |
 Created by Intishar Kazi, Meghan Chenoweth, Didier Jutras-Aswad, Keith Ahamad, M. Eugenia Socias, Bernard Le Foll, Rachel TyndaleMethadone and buprenorphine/naloxone are opioid agonist therapies for opioid use disorder treatment. Genetic factors contribute to individual differences in opioid response… |
| https://doi.org/10.1186/s12906-023-04312-1 |
| https://doi.org/10.1001/jamanetworkopen.2023.52233 |
| https://doi.org/10.1016/j.brs.2024.01.008 |
 Created by Heidar Sharafi, Hamzah Bakouni, Christina McAnulty, Sarah Drouin, Stephanie Coronado-Montoya, Arash Bahremand, Paxton Bach, Nadine Ezard, Bernard Le Foll… |
| https://www.cmaj.ca/content/196/6/E187 |
